Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
Takayuki Inoue, Masataka Morita, Takashi Tojo, Akira Nagashima, Ayako Moritomo, Hiroshi Miyake
Index: Bioorg. Med. Chem. 21(13) , 3873-81, (2013)
Full Text: HTML
Abstract
Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50=0.019 μM, rat IC50=0.0051 μM). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema.Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
Related Compounds
Related Articles:
2007-06-28
[J. Med. Chem. 50(13) , 3143-7, (2007)]
One-pot synthesis of N2-aminoprotected 6-substituted and cycloalka[d] 4-trifluoromethyl-2-acetylaminopyrimidines. Bonacorso HG, et al.
[J. Heterocycl. Chem. 45(2) , 483-87, (2008)]
Bonacorso HG, et al.
[Lett. Org. Chem. 4(7) , 495-99, (2007)]
Easy and regioselective access to dimethyl acetal-protected heterocycles and their efficient allylation reactions mediated by allylaluminum reagent. Bonacorso HG, et al.
[ARKIVOC 4 , 291-305, (2013)]